Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: CIHR - ICR / Cancer Research Society Partnership - Res. Grants - Breast Cancer

University of Calgary

$65,000.00

Enhancing T cell-based treatments in breast cancer using engineered type 2 innate lymphoid cells

EF 2023-24

Résumé
One Canadian succumbs to breast cancer every 90 minutes. New treatments using T cells, a subset of white blood cells, have shown promise in cancer therapy. However, only a fraction of patients suffering from breast cancer has benefited from these therapies. This proposal seeks to understand how type 2 innate lymphoid cells (ILC2s), another type of white blood cells, may improve the efficacy of T cell therapies. Our previous work identified ILC2s as a cell type involved in cancer control. This project aims to i) manipulate ILC2s to empower them with superior anti-tumour function and ii) test their efficacy in combination with T cell therapy in cells and animals. Collectively, our findings will define the therapeutic potential of ILC2s in combination with T cell treatment with the ultimate goal of improving breast cancer patient outcomes.
Programme
CIHR - ICR / Cancer Research Society Partnership - Res. Grants - Breast Cancer
Bénéficiaire
Emplacement
Alberta, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
516992
Name
Jacquelot Nicolas
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Partnername
Cancer Research Society Inc.; Cancer Research Society Inc.
Instname2
Cancer Research
Prcname2
Special Cases
Projecttitle
Enhancing T cell-based treatments in breast cancer using engineered type 2 innate lymphoid cells
Programtype2
Operating Grants
Orgnameinp2
University of Calgary
Cihramount2
$65,000
Cihrequipment2
$0
Programname2
CIHR - ICR / Cancer Research Society Partnership - Res. Grants - Breast Cancer
Keyworddelim
Breast Cancer
Abstract
One Canadian succumbs to breast cancer every 90 minutes. New treatments using T cells, a subset of white blood cells, have shown promise in cancer therapy. However, only a fraction of patients suffering from breast cancer has benefited from these therapies. This proposal seeks to understand how type 2 innate lymphoid cells (ILC2s), another type of white blood cells, may improve the efficacy of T cell therapies. Our previous work identified ILC2s as a cell type involved in cancer control. This project aims to i) manipulate ILC2s to empower them with superior anti-tumour function and ii) test their efficacy in combination with T cell therapy in cells and animals. Collectively, our findings will define the therapeutic potential of ILC2s in combination with T cell treatment with the ultimate goal of improving breast cancer patient outcomes.
Competitiondate
202402
Approvedterm2
2 yrs 0 mth
Pinamesdelim
Jacquelot, Nicolas
Approvedterm
2 ans 0 mois
Cihrcontribution2
ICR~ $65,000~ $0~